Japanese Dietary Supplement: Nichi Glucan, an Immune Booster in Covid-19
A unique Beta 1,3-1,6 Glucan based Japanese health supplement, produced by black yeast, Aureobasidium Pullulans, could strategically help tackle Covid-19 in people with comorbid conditions like diabetes, kidney and heart diseases, as published in Frontiers in Immunology Journal recommending clinical studies (https://www.frontiersin.org/articles/10.3389/fimmu.2020.01548/abstract ), for validation. This AFO-202 strain produced “Nichi Glucan” enhanced the immunity by increasing Natural Killer (NK) cells and anti-viral cytokines of healthy people, cancer patients and elderly, in three different studies in Japan. Encouraging outcome of earlier studies inspired us to hypothesize that, benefits of this food supplement in boosting the immunity could help during this pandemic, said Dr. Nobunao Ikewaki, a co-author.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005239/en/
Analyzing the intricacies and weakness of immune system in people with comorbid conditions, making them vulnerable to severe complications when infected by SARS-COV-2, scientists say that immune system must protect the body from pathogens like viruses, but shouldn’t over-act causing hyper inflammation leading to cytokine storm ensuing in respiratory failure or complications like stroke. Nichi Glucan having been found to boost protective factors like Cytotoxic T Cells and immunoglobulins, while controlling those lead to hyper inflammation through sFas and Treg cells, balancing as immunomodulator, has potentials worth clinical studies during this global health crisis, they opine.
Unique advantages of this biological response modifier glucan are attributed to its purity, being produced as an exo-polysaccharide and its water solubility. Nichi Glucan is manufactured in a GMP factory in the banks of upstream Niyodo river in Kochi prefecture. "Pristine water of this region is a key ingredient for production, making Nichi Glucan a nature's gift," says Mr. Takashi Onaka, President, Sophy Inc., the manufacturer.
Approved as food additive in 1996 after conforming to all safety norms of Japanese standards, Nichi Glucan isn’t a drug or cure to any illness. However, in the present situation, without vaccines to prevent or drugs to tackle the Covid-19 virus or its complications, it could be tried in studies to confirm efficacy in helping the immunocompromised vulnerable population through immune enhancement, comment the authors. Further research is underway to develop newer versions with higher adhesion for improvised immune stimulation. GN Corporation, the exclusive worldwide exporter, co-applicants to a patent with Sophy Inc., are looking for country-wise partners for further research & distribution (www.nichiglucan.com ).
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SKILLING2.7.2020 15:09:08 CEST | Press release
Skilling Launches MT4
CA-ZYNGA2.7.2020 15:07:08 CEST | Press release
Zynga Closes Transformational Acquisition of Istanbul-based Peak; Expands Forever Franchise Portfolio with Toon Blast and Toy Blast
SMITHS-DETECTION2.7.2020 11:02:07 CEST | Press release
Smiths Detection launches iCMORE algorithms for lithium batteries and dangerous goods for HI-SCAN 10080 XCT
EUSA-PHARMA2.7.2020 10:02:10 CEST | Press release
EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome
DEENOVA2.7.2020 09:36:08 CEST | Press release
Deenova Multiplies its Pharmacy Automation Market Presence into 7 European Countries
ADVA2.7.2020 09:02:06 CEST | Press release
Telstra Wholesale deploys ADVA technology in Australian-first Ethernet service
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom